Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Stock Information for Acorn International Inc. ADS

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acorn International Inc. ADS

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.